Background: The manipulation of gut microflora composition and activity by probiotics could modify the enzymatic
activity of intestinal bacteria. In this study, we sought to investigate the influence of probiotic treatment on
sulphasalazine (SSZ) excretion in inflammatory bowel disease (IBD) patients.
Methods: Newly diagnosed IBD patients were randomised in two groups; half of subjects were treated with SSZ and
other half were treated with combination of SSZ and probiotics. At the each visit, patients were assesed clinically
andfecal samples and total volume of 24 h urine was measured and noted. Urine samples were collected and analized
by liquid chromatography-mass spectrometry/mass spectrometryfor determination of SSZ and its metabolites. The
enzymatic activity of azoreductase by intestinal bacteria in the fecal contents was determined spectrophotometrically.
Results: Urinary levels of SSZ and its metabolites showed no statistically significant changes after probiotic
administration. Azoreductasa activities, in both experimental groups, decreased comparing with pretreatment values
in both cultivation conditions. Transient colonization with Bifidobacterium BB12 was confirmed in 22% of samples.
Lactobacillus rhamnosus LGG did not show transient colonisation of the digestive tract.
Conclusions: Co-administration of probiotics in patients treated with SSZ did not change the amounts of execreted
SSZ and its metabolites.